PAR · GNFT.PA
Genfit S.A.
€11.40-€0.06 (-0.52%)
Genfit S.A.’s quoted price sits in the upper half of its reported 52-week range, 26.36% below the high.
Loading market information…
PAR · ABNX.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
ABIONYX Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 63.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ABIONYX Pharma S.A.’s next earnings report is currently expected on Mar 16, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ABIONYX Pharma S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2023 | May 17, 2023 | -€0.06 | €2.62M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€11.40-€0.06 (-0.52%)
Genfit S.A.’s quoted price sits in the upper half of its reported 52-week range, 26.36% below the high.
€4.26-€0.12 (-2.63%)
Median Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
€0.72-€0.01 (-1.63%)
Transgene S.A.’s quoted price sits in the lower half of its reported 52-week range, 51.8% below the high.
€1.29+€0.01 (+0.63%)
Innate Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.81% below the high.
€1.10-€0.03 (-2.3%)
Cellectis S.A.’s quoted price sits in the lower half of its reported 52-week range, 76.8% below the high.
€1.27+€0.02 (+1.59%)
Crossject S.A.’s quoted price sits in the lower half of its reported 52-week range, 52.81% below the high.
€3.06-€0.06 (-1.99%)
Adocia S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.29% below the high.
€8.90+€0.10 (+1.14%)
Sensorion S.A.’s quoted price sits in the lower half of its reported 52-week range, 77.97% below the high.
